SELLAS Receives EMA Orphan Drug Designation For SLS009 For Treatment Of Peripheral T-Cell Lymphomas
Author: Benzinga Newsdesk | August 06, 2024 08:45am
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for SLS009, a novel, and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) peripheral T-cell lymphomas (PTCL).
Posted In: SLS